65,437 trials
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 — 0; 0; 0; 0 Participants
Asthma
Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — -0.043; 0.232; 0.229; 0.221 Liters — p=<0.001
Postoperative Pain
Primary: Complications of Peripheral Nerve Block — 7; 14 participants — p=<0.05
Contraception
Primary: Cmax (Maximal Serum Concentration of Medroxyprogesterone Acetate (MPA)) — 0.953 ng/mL
Asthma
Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — 0.137; 0.239; 0.266; 0.341 Liters — p=0.095
Myocardial Infarction · Chest Pain
Primary: Hospital Time to Treatment for Patients With Unstable Angina/Non-STEMI — 23; 31 minutes
Onset and Duration of a Digital Nerve Block
Primary: The Change in the Average Finger Temperature From Baseline to Post-intervention. — -1.35; 0.93 degrees centigrade
Patients Receiving Fractionated Stereotactic Radiotherapy · for Brain Tumors
Primary: Distance From Ideal to Center of GTC Frame and BrainLab Thermoplastic Mask With Respect to Average and Variability — 2.00; 3.17 millimeters
Pulmonary Disease, Chronic Obstructive
Primary: Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean — 1.05; 0.92; 0.70; 0.90 Exacerbations per participant per year — p=0.181
Atopic Dermatitis · Pruritus
Primary: Pruritus VAS Scores at Baseline, Week 2 and Week 4 — 7.8; 7.5; 6.10; 5.9 units on a scale
Sickle Cell Disease
Primary: Change in Total Cholesterol Level — -16; -18; -18 mg/dL
Hepatitis B
Primary: Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48 — 79; 18; 149; 109 Participants — p=<0.0001
Acute Renal Failure
Primary: 60-day All-cause Mortality — 302; 289 participants — p=0.47
Epilepsy
Primary: Percentage of Participants Retained to Topiramate Treatment — 71.56 Percentage of participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean Heart Rate 0-4 Hours Post-dose at the End of the 28-day Treatment Period — -5.7; -5.1 Beats per minute (bpm)